3rd Cancer Epigenetics Conference, San Francisco, November 6-8, 2013
Register 3 for the price of 2 with the coupon code rcdvb!

Dear Colleague,

Industrial interest in applying and translating epigenetic science to cancer therapy is growing at an exponential pace with many large and small companies already heavily invested in the field. Fortunately, epigenetics arrives as a science in a more collaborative era and may even have the potential to impact disease areas beyond cancer in the future. The fundamental underpinning science of the epigenome will likely be solved through partnership between academic and industrial labs.

GTC’s 3rd Cancer Epigenetics Conference, one of two parallel tracks of the 2nd Cancer Summit – Novel Approaches to Drug Discovery on November 6-8 in San Francisco, CA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.

Below are the sessions of the 3rd Cancer Epigenetics Conference:

I. Epigenetic Mechanisms in Cancer
II. Epigenetic Biomarkers and Diagnostics
III. Novel Epigenetic Targets in Early Development
IV. New Clinical Development of Epigenetic Drugs
V. Epigenetic Tools and Technologies


The conference will run parallel with the 8th Cell Based Assay & Screening Technologies as part of the 2nd Cancer Summit - Novel Approaches to Drug Discovery. Register for the summit and gain access to both conferences!



We look forward to seeing you at the conference!


Sincerely,

2013 Cancer Epigenetics Conference Organizing Committee
GOLD SPONSORS

MEDIA PARTNERS
What Past Delegates said:

“Fantastic opportunity to see the very latest research in epigenetics drug-discovery.” - Rab Prinjha, VP Head of Epinova DPU, GSK

"The conference was a huge success, bringing together the top-leaders and innovators in the protein kinase field, where new screening technologies and the most late-breaking clinical kinase targeting drugs were disclosed. The group is growing in numbers each year, but still remains quite manageable to allow for one-on-one interactions and networking. This conference has become indispensable for those in the kinase drug discovery field." - Mark Mulvihill, Associate Director of Chemistry, Oncology, OSI Pharmaceuticals

"The meeting provides an excellent snapshot of the up-to-date state of kinase drug discovery with inputs from both academia and industry. It covers all aspects of the field starting from discussion of well established as well as new emerging kinase targets to the novel classes of small molecule inhibitors to new exciting technologies to study kinases. It also provides ample opportunities for networking and establishing new collaborations." - Dr. Alexei Degterev, Assistant Professor, Tufts University

“An excellent meeting with good organization and top quality speakers and attendees from academia and bio-pharmaceutical as well and biotechnology industry.” - Pfizer



Attend All GTC Conferences for One Year for only $3,995 ($1,990 for Acad/Govt).
Click here to sign up!